Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant ...

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...

With Watchman, Boston Scientific estimates a 20% compound annual growth rate (CAGR) in 2025 with a high market share. Mahoney ...

The device uses acoustic pressure waves created in a balloon catheter to fracture calcium buildup on the insides of blood vessels. Boston Scientific, the third-largest medical device-maker in the ...

Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn ...

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Marie ...

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price ...

Boston Scientific (NYSE: BSX) today reported data from separate studies backing its Farapulse and Watchman FLX systems.

Boston Scientific Corporation (BSX) shares rise on acquisitions – earnings due in early February.

Boston Scientific Corporation today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based ...

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and ...

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients with paroxysmal atrial fibrillation (AF) as the company looks to ...